Thomas De Raedt

An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB

Junxia Min, A. Zaslavsky, Giuseppe Fedele et al. · Nature Medicine · 2010 · 379 citations · Full text

Medicine, Cancer Biology, Oncology +12

Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors

Thomas De Raedt, Zandra E. Walton, Jessica L. Yecies et al. · Cancer Cell · 2011 · 257 citations · Full text

Medicine, Cancer Biology, Oncology +16

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

Eline Beert, Hilde Brems, Bruno Daniëls et al. · Genes Chromosomes and Cancer · 2011 · 252 citations

Medicine, Molecular Genetics, Oncology +17

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

Haikuo Zhang, Jun Qi, Jaime M. Reyes et al. · Cancer Discovery · 2016 · 128 citations · Full text

Medicine, Genetics, Oncology +17

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i> -, and <i>NF1</i> -Mutant Melanomas

Ophélia Maertens, Ryan Kuzmickas, Haley E. Manchester et al. · Cancer Discovery · 2019 · 105 citations · Full text

Medicine, Cancer Biology, Oncology +17